Cartesian Therapeutics
RNAC
102 hedge funds and large institutions have $71.9M invested in Cartesian Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 41 reducing their positions, and 17 closing their positions.
318% more call options, than puts
Call options by funds: $188K | Put options by funds: $45K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.08% less ownership
Funds ownership: 1.63% → 1.55% (-0.08%)
4% less funds holding
Funds holding: 106 → 102 (-4)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
32% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 41
61% less capital invested
Capital invested by funds: $186M → $71.9M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$2.77M |
| 2 |
Renaissance Technologies
New York
|
+$2.11M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$1.84M |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$1.7M |
| 5 |
Millennium Management
New York
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$3.09M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.36M |
| 3 |
Morgan Stanley
New York
|
-$966K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$815K |
| 5 |
Two Sigma Investments
New York
|
-$683K |
RNAC Hedge Fund Activity: Q1 2022 in Review
102 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2022, worth a combined $71.9M — down 61% from $186M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RNAC and 13 opened new positions — a net loss of 4 holders — while 41 trimmed existing stakes and 28 added.
The largest buyer was Endurant Capital Management, adding an estimated $2.77M. The largest seller was Marshall Wace, cutting an estimated $3.09M.
- 102 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2022, down from 106 in Q4 2021.
- Funds reported $71.9M of Cartesian Therapeutics stock for Q1 2022, down 61% quarter-over-quarter.
- 13 funds opened new Cartesian Therapeutics positions in Q1 2022 and 17 closed out, a net change of -4 holders.
- The largest Cartesian Therapeutics buyer in Q1 2022 was Endurant Capital Management, an estimated $2.77M added.
- The largest Cartesian Therapeutics seller in Q1 2022 was Marshall Wace, an estimated $3.09M sold.
Based on aggregated 13F filings for Q1 2022.